An alternatively spliced variant of mRNA for the human receptor for urokinase plasminogen activator  by Pyke, C. et al.
Volume 326, number 1,2,3, 69-74 FEBS 12660 
0 1993 Federation of European Biochemical Societies 00145793/93/$6.00 
July 1993 
An alternatively spliced variant of mRNA for the human receptor for 
urokinase plasminogen activator 
C. Pyke, J. Eriksen, H. Solberg, B. Schnack Nielsen, P. Kristensen, L.R. Lund and K. Dan0 
Finsen Laboratory, Rigshospitalet, Strandboulevarden 49, DK-2100 Copenhagen 0, Denmark 
Received 28 April 1993 
Using 3’ RACE (rapid amplification of cDNA ends), we have isolated a cDNA variant for the receptor for human urokinase plasminogen activator 
(uPAR). The deduced protein includes the amino-terminal ligand binding domain in uPAR, but lacks the carboxy-terminal membrane attachment 
by a glycolipid anchor. Genomic DNA analysis showed that the uPAR mRNA variant is generated by alternative splicing. The new variant mRNA 
is expressed in various human cell lines and tissues and both variants are up-regulated by phorbol ester in A549 cells. We propose that the 
alternatively spliced uPAR mRNA encodes a soluble uPA binding protein, the possible function of which is discussed. 
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1. INTRODUCTION 
The urokinase pathway of plasminogen activation is 
involved in tissue remodelling under normal and pa- 
thological conditions, including cancer invasion [l]. A 
specific cell surface receptor for UPA (uPAR) has been 
identified on human monocytes and on a variety of 
cultured cell lines of neoplastic origin [24]. Receptor 
binding of UPA strongly enhances plasminogen activa- 
tion and uPAR plays a crucial role in cell surface prote- 
olysis [5]. The receptor was recently characterized in 
details: its I,4 kb mRNA [6] is encoded by a gene lo- 
cated on the long arm of chromosome 19 [7] and is 
translated into a protein consisting of 313 amino acid 
residues and a signal peptide. Based on alignment of 
cysteines, the receptor has been shown to consist of 
three homologous repeats of which the amino-terminal 
constitutes the ligand-binding domain [8]. uPAR is a 
highly glycosylated protein, which is linked carboxy- 
terminally to the cell membrane by a glycosylphosphat- 
idyl inositol (GPI) lipid anchor [9]. In the mouse, evi- 
dence has been provided for the existence of a UPA 
receptor homologous to human uPAR (muPAR1) 
[lO,l 11, as well as a mouse uPAR mRNA variant 
(muPAR2) produced by alternative splicing in the mid- 
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dle of the second repeat and encoding a molecule iden- 
tical to muPAR in the UPA binding domain but lack- 
ing the GPI anchoring, and probably representing a 
soluble form of muPAR [lo]. We now report the iden- 
tification of a variant form of human uPAR mRNA 
(uPAR2) likely to represent a human functional analog 
of mouse uPAR2, but arising by alternative splicing in 
the middle of the third domain. 
2. MATERIALS AND METHODS 
2.1. Materials 
pBluescriptKS(+) plasmid vector, competent E. coli strain JM109 
and a human genomic cosmid library were from Stratagene, La Jolla, 
CA. All other materials were those previously described [lo]. RNA 
from human tissues and cultured cells was prepared as described 
[10,12]. 
2.2. Primers 
The following synthetic oligonucleotide primers were used for 
RACE amplification and for generating PCR products (prefix ‘c’ 
designates a complementary primer). (i) Primers common to both 
uPAR1 and uPAR2 (numbers in brackets refer to Roldan et al. [6]): 
90-8 (386405) ~90-9 (576597) 91-02 (6255645) 91-07 (113-130) 
92-13 (l-22). (ii) uPARl-specific primers (numbers in brackets refer 
to Roldan et al. [6]): ~91-03 (933-955) 91-04 (901-924) ~91-05 (1255- 
1276) 92-305 (128771309). (iii) uPAR2-specific primers (numbers in 
brackets refer to Fig. 2): ~91-101 (1025-1045) ~92-306 (921-933) 
92-311 (104221062), ~92-304 (8 16842). (iv) RACE downstream 
primers: dT,,-adapter: S’GACTCGAGTCGACATCGA-dT,,; 
adapter: S’GACTCGAGTCGACATCGA. 
2.3. RACE amplification of3’ ends 
For RACE amplification of total RNA extracts [13] the dT,,- 
adapter primer was used for reverse transcription and this adapter 
primer, together with the uPAR cDNA-specific primer, 91-02, was 
used for PCR-amplification. The PCR reaction mixture was then 
analysed on a 1% agarose gel containing ethidium bromide. 
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2.4. Sequencing RACE products 
DNA from the RACE amplification contained in agarose gel pieces 
was purified (Geneclean II, Bio 101 Inc., La Jolla, CA), cut with 
restriction enzymes Apal and CluI and subcloned into 
pBluescriptKS(+) plasmid vector using standard techniques [14]. 10 
pg DNA from the clones pIa and pIIb was used for sequencing by the 
dideoxy method [15]. Sequence homology searching was performed on 
the EMBL and Swissprot databases (updated 14 April 1993) using the 
FastA/TFastA method [16]. 
2.5. PCRfor uPAR2 mRNA 
DNase I-treated purified RNA from human cells and tissues was 
used for reverse transcription performed as the RACE first strand 
synthesis, except that the RACE primer was substituted by primer 
c9 I-10 1. In the following PCR amplification step, l/20 of the reaction 
mixture was used with primers ~91-101 and 91-07. 
2.6. In vitro translation 
For generation of synthetic RNA corresponding to uPAR1 and 
uPAR2 mRNA, the respective cDNA coding sequences were cloned 
into pBluescriptKS(+). uPAR1 cDNA for this purpose was prepared 
by PCR amplification of full-length uPAR cDNA (clone p-uPAR-1 
[6]) using primers 92-13 and 91-05. uPAR2 cDNA was prepared as 
follows. First, the 5’ end was prepared by cutting uPAR cDNA with 
NcoI (cutting uPAR cDNA at position 718) and isolating the 718 bp 
DNA fragment. Next, the 3’ end was made by PCR amplification of 
pIIb using primers 91-02 and 91-101, cutting the resulting product 
with NcoI and isolating the fragment of 321 bp. Finally the two ends 
were ligated with T4 DNA ligase. Both uPAR1 and uPAR2 cDNA 
was then blunt-end cloned into pBluescriptKS(+)[14]. Purified plas- 
mid DNA of both constructs was verified by dideoxy sequencing using 
T3 and T7 primers. For in vitro translation, unlabelled sense RNA was 
prepared and used for translation in rabbit reticulocyte lysate as de- 
scribed [lo]. l/20 of each reaction mixture was analysed by SDS- 
PAGE and fluorography. 
2.7. Sequencing selected regions of’ the uPAR gene 
500,000 E. coli colonies of a human genomic cosmid library were 
screened on Genescreen nylon filters using a “P-1abelled PCR frag- 
ment covering the entire coding region of uPAR. The hybridization 
and washing conditions were as recommended by the manufacturer. 
Two positive clones were obtained: CosHUR07 and CosHURlO. 
DNA from cosmid clone CosHUR07 was used for PCR amplifica- 
tion with primers 92-305 and ~92-306. The resulting approximately 
750 bp product was blunt-end cloned into pBluescriptKS(+) and se- 
quencing was performed as above. Inverse PCR of flanking regions 
[17] was performed on DNA from CosHUR07. In brief, 10 pg of 
purified DNA was cut with &I, self-ligated with T4 DNA ligase and 
amplified with the uPAR2-specific primers ~92-304 and 92-311. A 
resulting -900 bp PCR fragment was blunt-end cloned into 
pBluescriptKS(+) plasmid and sequenced as above. 
Genomic human DNA from human umbilical cord endothelial cell 
line, HUVEC, was used for sequencing the region amplified with 
primers 90-8 and ~90-9, corresponding to the region in the mouse 
genome where the muPAR2-specific coding sequence is located [lo]. 
2.8. RNase protection assay 
Plasmid pIIb (see section 2.4.) was linearized with ApaI and a 
radiolabelled RNA antisense probe was prepared by transcription 
using [ZZP]UTP and T7 polymerase as described [18], except that unla- 
beled UTP was added in a lo-times molar excess over [“PIUTP. Two 
non-radiactive control RNAs to serve as size markers were prepared 
by transcription in the sense direction of pIIb and pHUR06 (a 584 bp 
BamHIIBumHl uPAR1 cDNA fragment [18]). RNase protection 
assay, using 2.5 pg ethanol precipitated and DNase I-treated poly(A) 
RNA from A549 cells grown with or without PMA was performed as 
described [14]. Protected mRNA regions were analysed on a denatur- 
ing polyacrylamide gel and autoradiography. 
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Fig. 1. 3’ end RACE amplification of RNA from HT1080 cells with 
a uPAR specific primer. Total RNA from HT1080 cells was amplified 
with the RACE technique using an upstream primer corresponding to 
nucletide 625-645 [6] in uPAR cDNA. The amplification products 
were analyzed by agarose gel electrophoresis and stained with ethid- 
ium bromide. Two bands of approximately 450 and 750 bp are seen. 
3. RESULTS 
3.1. IdentiJicution of a variant of uPAR mRNA by 
RACE amp&cation 
RACE amplification of cDNA corresponding to the 
3’ end of uPAR mRNA was performed with a primer 
corresponding to nucleotides 625-645 [6] on total RNA 
purified from HT1080 cells. Analysis of the RACE 
products on a ethidium bromide-stained agarose gel 
revealed two bands of approximately 450 and 750 bp 
(Fig. 1). Both products were subcloned into a sequenc- 
ing plasmid vector and the nucleotide sequence was 
determined on clones pIa and pIIb, containing the 750 
bp and the 450 bp inserts, respectively. The 750 bp 
product was, as expected, identified as the 3’ end of 
uPAR cDNA [6]. The 450 bp product consisted of 153 
bp showing complete sequence homology with uPAR 
cDNA (position 650-803) followed by a 268 bp se- 
quence unrelated to uPAR cDNA and ending in a 
poly(A) sequence (Fig. 2). We concluded that this repre- 
sented the 3’ end of a 1,071 bp-long nucleotide variant 
of uPAR cDNA. This new cDNA variant was termed 
uPAR2, and the previously cloned variant uPAR1. 
uPAR2 contains an open reading frame with a transla- 
tion stop codon located in position 891-93 and is pre- 
dicted to yield a protein identical to uPAR1 in amino 
acid residues l-252 but differing from uPAR1 in the 
carboxy-terminal 29 residues (Fig. 2). No homologies of 
the uPAR2-specific sequence to any nucleotide or pro- 
tein sequences were found by a search in the EMBL and 
Swissprot data bank. A hydrophobicity plot of the 
uPAR2-specific carboxy-terminal by the algoritm of 
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uPAR1 cDNA 
uPAR2 cDNA 
uPAR1 protein 
uPAR2 protein 
uPAR1 cDNA CGCCTCAATGTGCCAACATGCCCACCTGGGTGACGCCTTCAGCATGAACCACATTGATGT 
uPAR2 cDNA TACTGCCCTGAGACCACCATGCTGTGAGGAAGCCCAAGCTACTCATGTATAAATGCCATG 
uPAR1 protein AlaSerMetCysGLnHisA~aHisLeuG~yAspALaPheSerMetAsnHisILeAspVal 
uPAR2 protein ThrAlaLeuArgProProCysCysGLuGLuALaGlnAlaThrHisValEnd 
uPAR1 cDNA CTCCTGCTGTACTAAAAGTGGCTGTAACCACCCAGACCTGGATGTCCAGTACCGCAGTGG 
uPAR2 cDNA TGGAGATAGAGCCCCAGATGTTTCAGCCATCTCAGCCCAGGCACCAGACAAGTGGGTGAA 
uPAR1 protein SerCysCysThrLysSerG~yCysAsnHisProAspLeuAspVaIG~nTyrArgSerGly 
uPAR1 cDNA GGCTGCTCCTCAGCCTGGCCCTGCCCATCTCAGCCTCACCATCACCCTGCTAATGACTGC 
uPAR2 cDNA GAAGCCACCTTGGACATGTAGCCCCACGAGATGTGATATAGAGAAGAAACAGGAAACTTG 
uPAR1 protein ALaALaProGLnProGLyProALaHisLeuSerLeuThrILeThrLeuLeuMetThrALa 
uPAR1 cDNA CAGACTGTGGGGAGGCACTCTCCTCTGGACCTAAACCTGAAATCCCCCTCTCTGCCCTGG 
uPAR2 cDNA GCTATATTAGTTTCCTAGGGCTGCCTGTGATAAATTATTACGAACTTTATAAAAAAAAAA 
uPAR1 protein ArgLeuTrpGlyGLyThrLeuLeuTrpThrEnd 
uPAR1 cDNA CTGGATCCGGGGGACCCCTTTGCCCTTCCCTCGGCTCCCAGCCCTACAGACTTGCTGTGT 
uPAR2 cDNA AAAAAAAAAAAAAAA 
'The total number of nucleotides in uPAR1 cDNA is 1368. 
GGTAGCCACCGGCACTCACGAACCGAAAAACCAAAGCTATATGGTAAGAGGCTGTGCAAC 
. . . . . . . . . . . . . . . . . . . . AACGCTCACTCTGGGGAAGCTGGTTGCCATGTAAAAGTAC 
ValALaThrGLyThrHisGLuProLysAsnGlnSerTyrMetValArgG~yCysAlaThr 
__ - -_ - - ArgSerLeuTrpGLySerTrpLeuProCysLysSerThr 
840 
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Fig. 2. Sequence of the 3’ ends of the two uPAR cDNAs identified in Fig. 1 and the corresponding deduced amino acid sequences. The data are 
aligned with and numbered according to the previously reported uPAR cDNA and protein sequences [6,8]. (-) and (.) designates the parts of uPAR2 
that are identical to uPARl. 
Kyte and Doolittle [19] yielded values close to the neu- 
trality line, indicating that the putative uPAR2 protein 
is a soluble form of uPAR. No potential glycosylation 
sites are present in the 29 residue carboxy-terminal end 
of the uPAR2 protein. 
3.2. Gene organization 
To study whether the two uPAR variants were the 
result of alternative splicing, a genomic human uPAR 
DNA clone was isolated from a cosmid library, by 
screening with a cDNA probe covering the entire coding 
region of uPAR1 cDNA, PCR amplification with 2 
primers specific for uPAR1 and uPAR2, respectively, 
and inverse PCR amplification of the regions flanking 
the uPARZspecific sequence. Sequencing of a part of 
this genomic clone revealed the presence of a 72 bp 
sequence identical to the 3’ end of uPAR1 mRNA and 
a 268 bp sequence identical to the 3’ end of uPAR2 
mRNA. These two sequences are separated by a 578 bp 
sequence which is not found in any of the two uPAR 
mRNA variants and which contains an ah sequence. 
Splice junction consensus sequences are present at a 
position &ap;lO bp downstream from the polyadenyla- 
tion site in uPAR1 mRNA, at the junction between the 
new sequence and the uPAR2-specific sequence, and at 
a position &ap;lO bp downstream from the polyadenyl- 
ation site in the uPAR2-specific sequence (Fig. 3). These 
findings indicate that the two uPAR mRNA variants 
arise by alternative splicing of two mutually exclusive 
3’ end exons, each containing a polyadenylation site and 
a carboxy-terminal coding sequence (Fig. 3). 
In the murine system the uPAR mRNA variants, 1 
and 2, arise by alternative splicing at nucleotide 480 in 
domain 2 [lo]. Human genomic uPAR DNA from the 
region corresponding to this position was also isolated 
by PCR techniques. Sequencing of this DNA revealed 
the presence of an approximately 900 bp-long intron 
after nucleotide 5 16. No open reading frame sequence 
analogous to that found for muPAR was detected, 
however, indicating that this region in the human uPAR 
gene is not involved in a similar RNA splicing event 
(results not shown). 
3.3. In vitro translation of uPAR mRNA variants 
Full-length sense RNA for uPAR1 and uPAR2 was 
prepared and translated in rabbit reticulocyte lysates. 
SDS-PAGE and fluorography showed generation of 
proteins with molecular weights of = 35,000 and 
= 31,000 as expected for uPAR1 and uPAR2, respec- 
tively (Fig. 4). 
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A. 
92-305 
genomic clone 
uPAR1 cDNA 
CTGTTGTGTTGTTGTTATTAATTAATATTCATATTATTTATTTTATCTTACATAAAGATTT 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
P 1 
TTGTACCAGTGGACAAGGCCAGGTATGCCCTTCTTTGTAGTGTCTATCTTTGGGAGGATAA 
. . . . . . . . . . . ..AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
60 
1352 
genomic clone 
uPAR1 cDNA 
120 
1400 
genomic clone 
genomic clone 
ATGGTGGGGGACACCTTTTCACAGGCTCCTGGAATCAGGGGTCATGTTTGAGGCCCCTGCC 180 
TAGGTTGGAAGTCCTCCTGGGGGCTGCCTCCACATCTATTTCTGGACTCCAAATGCTGACA 
GACAGGAGCACTGCCATCTTGAACAAACACCACCATTCTTAGTTCCTCT~TGATTAAAATC 
240 
genomic clone 
genomic clone 
genomic clone 
300 
GGCTAAATCCGGACGTGGTGGTGGGTGACTGTAACTCAGCTACCGGAGGGCTGAGGCAGGA 360 
GATCGCTTGAACCAGAGAGAGTGTAGTGAGCAAGATCACCACTGCTAGAACCGTGAGACAT 420 
genomic clone TCCAAAAAAAAAAAAAAAAGACTCTCATGATTGGGCATGAGGACAGTCTGTTAGGCTTCTC 480 
genomic clone TAATGACATATCACACTTGCACGTAGTGGCTTAAAGAATGGAGGTCTGTACTTCTGCCTCT 540 
genomic clone TGATATGAGTGACTCTGTGACTGCTTTGACCAGTAGATGGTGGAAGTTTTGCTGTGCTATG 600 
1 
genomic clone 
uPAR2 cDNA 
TTCTGGAACCAAGTTTTAAGAAACTTTCATTTTTCACTTTCTGAATCTTAGAACGCTCACT 
. . . . . . . . . . 
~92-304 
660 
810 
genomic clone CTGGGGAAGCTGGTTGCCATGTAAAAGTACTACTGCCCTGAGACCACCATGCTGTGAGGAA 720 
uPAR2 cDNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 870 
92-311; ~92-306 
genomic clone GCCCAAGCTACTCAGATAAAGCCAAGTGGAGTATAGAGCCCCAGATGTTTCAGCCATCTCA 780 
uPAR2 cDNA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 930 
genomic clone 
uPAR2 cDNA 
GCCCAGGCACCAGACAAGTGGGTGAAGAAGCCACCTTGGACATGTAGCCCCACGAGATGTG 
z.................... . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
ATATAGAGAAGAAACAGGAAACTTGGCTATATTAGTTTCCTAGGGCTGCCTGTGATAAATT 
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
P 1 
ATTACGAACTTTATAACTAACACATTGTGTGTCCTATATCAAAACATCATGGAAGGACAGG 
. . . . . . . . . . . ..AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA 
840 
990 
genomic clone 
uPAR2 cDNA 
900 
1050 
genomic clone 
uPAR2 cDNA 
960 
1097 
genomic clone CACAGTGGCTCATCCTGTAGTCCTAGCACTTC 992 
B 
s I 2 3 I 
uPAR1 
Genomic clone 
uPAR2 
mRNA 
protein 
* ’ 1 ’ 2 
Fig. 3. (A) Sequence of part of the uPAR gene and the corresponding parts of uPAR1 and uPAR2 cDNA. Sequence l-786 in the genomic DNA 
is obtained from a PCR fragment produced by conventional amplification of DNA from cosmid clone CosHUR07 using primers 92-305 (located 
in the far 3’ end of uPAR1) and ~92-306 (located in the uPAR2-specific 3’ end). The remainder of the sequence is derived from a fragment obtained 
by inverse PCR on the same clone using the uPAR2-specific primers, ~92-304 and 92-311. (.) indicates sequences in uPAR1 and uPAR2 cDNA 
identical to the genomic sequence, numbered according to Fig. 2. Primers used for generation of PCR-fragments are underlined. (1) indicates splice 
junctions. (4) and (t) indicate the start and end of an ah sequence. P indicates polyadenylation sites. (B) Schematic representation of the 
relationship between the partial genomic uPAR sequence, the uPAR1 and uPAR2 mRNAs, and the deduced protein sequences. Hatched 
bars = uPARl-specific sequences uPAR1; tiled bars = uPAR2-specific sequences; black bars = sequences common to uPAR1 and uPAR2; white 
bars = intron sequences spliced out in both uPAR1 and uPAR2. In the proteins, ‘s’ indicates the signal peptide, ‘l-3’ the three homologous repeats, 
and ‘r’ a peptide removed during post-translational attachment of a glycolipid anchor. 
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Fig. 4. In vitro translation products of uPAR1 and uPAR2 synthetic 
RNA using rabbit reticulocyte lysate and [“Slcysteine. Analysis by 
SDS-PAGE and fluorography. Protein bands of the expected sizes are 
generated by uPAR1 (lane 1) and uPAR2 RNA (lane 2). The position 
of protein size markers are indicated on the right and the apparent 
molecular weight of the translation products on the left. The addi- 
tional bands of lower molecular weight are probably caused by incom- 
plete terminations. No microsomes were added to the translation 
reactions. 
3.4. Detection of uPAR mRNA variants by PCR and 
RNase protection 
By PCR with a primer common to uPAR1 and 
uPAR2 (91-07) and a primer specific for uPAR2 mRNA 
(c91-101) uPAR2 mRNA was detected in the following 
human cells and tissues: U937 monocyte-like cells, 
HepG2 hepatocarcinoma cells, A549 lung carcinoma 
cells, alveolar macrophages, leukocytes and colon tissue 
(results not shown). 
Expression of the uPAR mRNA variants was also 
studied by RNase protection assay, using a radiolabeled 
antisense RNA probe containing a sequence common 
for uPAR1 and uPAR2, and a sequence specific for 
uPAR2. Analysis of poly(A)-purified RNA from A549 
cells cultured in the presence or absence of the phorbol 
ester PMA, showed that uPAR1, as well as uPAR2 
mRNA, was present in both preparations and that the 
PMA-treated cells clearly contained increased amounts 
of both mRNA variants in comparison with unstimu- 
lated cells (Fig. 5). RNase protection analysis of poly(A) 
RNA from HT1080 cells also confirmed the presence of 
both mRNA variants in these cells (results not shown). 
4. DISCUSSION 
The present study demonstrates the existence of a 
new variant of human uPAR mRNA, uPAR2. This 
variant and the previously identified uPAR1 mRNA 
variant arise by alternative splicing of two mutually 
exclusive 3’ end exons, each containing both a transla- 
tion stop codon and a polyadenylation site. 
The deduced amino acid sequence of uPAR2 mRNA 
comprises a protein which, in addition to a signal pep- 
tide, consists of 259 amino acid residues, the 230 residue 
amino-terminal sequence being identical to that of 
uPAR 1, while the 29 residue carboxy-terminal sequence 
is unique for uPAR2. We have previously found that the 
89 amino-terminal amino acid residues of uPAR1 con- 
stitutes the UPA binding domain [8] and that mature 
uPAR1 is linked to the cell surface by a GPI anchor 
attached at amino acid residue 282, 283 or 284 [9]. It is 
therefore likely that the putative uPAR2 protein has 
retained UPA binding activity and is a water-soluble 
secreted protein. 
uPAR2 mRNA is expressed in several cell types and 
tissues, as demonstrated by PCR and RNase protection 
analysis. In PMA-stimulated A549 lung carcinoma 
cells, uPAR2 mRNA of the expected size has also been 
detected by Northern blotting analysis (unpublished re- 
sults). Recombinant uPAR2 protein was produced by 
in vitro translation and showed the predicted molecular 
weight, thus confirming the presence of a translation 
stop codon. The expression of native uPAR2 protein 
remains to be investigated. 
In the mouse, two uPAR mRNA variants arise by 
alternative splicing of an intron with two different 
donor sites giving rise to a muPAR mRNA homolo- 
gous to the human uPAR1 mRNA, and a muPAR 
mRNA that encodes a 199 amino acid residue protein 
[lo]. The first 133 residues are identical to muPAR and 
include the UPA binding domain, while the last 66 resi- 
dues are unique for muPAR2. There are no homologies 
between the sequences unique for human and mouse 
uPAR2, but both lack potential GPI anchoring sites 
and both are hydrophilic. In spite of the different sites 
of and mechanisms of alternative splicing, the human 
and mouse uPAR2 proteins probably have two impor- 
tant properties in common: an intact UPA binding do- 
main and hydrophilicity. It is noteworthy that although 
different alternative splicing mechanisms are involved 
in the generation of the human and mouse uPAR2 
mRNA variants, the predicted donor splicing site in- 
volved in the human system (nucleotide 800, see Fig. 2) 
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activation at sites other than cell surfaces. Recent stud- 
ies suggest that uPAR1 enhances plasminogen activa- 
tion by participating in a formation of complexes be- 
tween pro-uPA and plasminogen at cell surfaces [21]. It 
is possible that the uPAR2 molecules serve a similar 
function at certain extracellular sites and that the 
uPAR2-specific sequences serve to locate the uPAR2 
molecules at these sites. 
503 BP 
-176 BP 
Fig. 5. RNase protection assay of poly(A) RNA from cultured human 
A549 lung carcinoma cells. An “P-1abelled uPAR2 antisense RNA 
probe (lane 1) was hybridized with poly(A)-enriched RNA from A549 
cells grown with (lane 2) or without (lane 3) PMA; 10 pg tRNA (lane 
4); uPAR2 sense RNA (503 bp of protected region of pIIb cDNA) 
(lane 5); and uPAR1 sense RNA (176 bp of protected region of a 
uPARl cDNA fragment) (lane 6). 
is located in the third repeat of uPAR1 at a position 
which exactly corresponds to the alternative splicing site 
(nucleotide 480) in the homologous second repeat in the 
murine receptor sequence [8,10]. 
The possible function of the uPAR2 molecules re- 
main to be investigated. Binding of UPA and the zymo- 
gen, pro-uPA, to uPAR1 plays a crucial role in cell 
surface plasminogen activation [5]. Recent studies have 
shown that monoclonal uPAR1 antibodies that inhibit 
uPA-binding also inhibit plasmin generation [20]. The 
putative uPA-binding, water-soluble and secreted 
uPAR2 molecules may therefore serve a physiological 
function as inhibitors of cell surface proteolysis by inhi- 
bition of the binding of UPA to uPAR1. Alternatively 
uPAR2 may have a function in inducing plasminogen 
Acknowl&ements: The excellent technical assistance of Britt Nagel, 
Jette Mandelbaum and Marianne Vallo Nielsen is gratefully acknowl- 
edged. This work was supported financially by the Danish Biotechnol- 
ogy programme, the Danish Cancer Society and the Danish Medical 
Research Council. 
REFERENCES 
Ill Dano, K., Andreasen, P.A., Grondahl-Hansen, J., Kristensen, P., 
Nielsen, L.S. and Skriver, L. (1985) Adv. Cancer Res. 44, 139- 
266. 
I21 
[31 
Vassalli. J.-D.. Baccino, D. and Behn, D. (1985) J. Cell Biol. 100, 
86692. 
Stoppelli, M.P., Corti, A., Soffientini, A., Cassani, G., Blasi, F. 
and Associan, R.K. (1985) Proc. Natl. Acad. Sci. USA 82,4939- 
4943. 
141 
[51 
161 
171 
181 
191 
UOI 
Vll 
Nielsen, L. S., Kellerman, G.M., Behrendt. N., Picone, R.. Dana, 
K. and Blasi, F. (1988) J. Biol. Chem. 263, 235882363. 
Ellis, V.. Pyke, C., Eriksen, J., Solberg, H. and Dana, K. (1992) 
Ann. NY Acad. Sci. 667, 1333 I. 
Roldan, A.L.. Cubellis, M.V., Masucci, M.T.. Behrendt, N., 
Lund, L.R., Dana, K., Appella, E. and Blasi, F. (1990) EMBO 
J. 9, 467474. 
Borglum. A.D., Byskov, A., Roldan, A.L., Ragno, P., Triputti, 
P., Cassani, G., Dano, K., Blasi, F., Bolund, L. and Kruse, T.A. 
(1992) Am. J. Hum. Genet. 50, 492497. 
Behrendt, N., Rsnne, E., Ploug, M., Petri, T., Lsber, D., Nielsen, 
L.S., Schleuning, W.-D., Blasi, F., Appella, E. and Dana, K. 
(1990) J. Biol. Chem. 265, 645336460. 
Ploug, M., Ronne, E., Behrendt, N., Jensen, A.L., Blasi, F. and 
Dana, K. (1991) J. Biol. Chem. 266, 1926.-1933. 
Kristensen, P., Eriksen, J., Blasi, F. and Dana, K. (1991) J. Cell 
Biol. 115. 176331771. 
[I21 
[I31 
u41 
(151 
1161 
u71 
Solberg, H., Lober, D., Eriksen, J., Ploug, M., Ronne, E., 
Behrendt, N., Dana, K. and Hoyer-Hansen, G. (1992) Eur. J. 
Biochem. 205, 451458. 
Lund, L.R., Romer, J.. Ronne, E.. Ellis. V., Blasi, F. and Dana. 
K. (1991) EMBO J. IO, 339993407. 
Frohman, M.A. (1990) in: PCR Protocols (Innis M.A., Gelfdnd, 
D.H., Sninsky, J.J., White, T.J., eds.) pp. 28-39, Academic Press 
Inc., San Diego. 
Sambrook, J., Fritsch, E.F. and Maniatis, T. (1989) Cold Spring 
Harbor, Cold Spring Harbor Laboratory Press. 
Sanger, F., Nicklen, S. and Coulson, A.R. (1977) Proc. Natl. 
Acdd. Sci. USA 74, 5463. 
Devereux, J., Haeberli, P. and Smithies, 0. (1984) Nucleic Acid 
Res. 12, 387-395. 
Ochman, H., Medhora, M,M,, Garza, D. and Hartl, D.L. (1990) 
in: PCR Protocols (Innis, M.A., Gelfand, D.H., Sninsky, J.J., 
White, T.J., eds.) pp. 219-227, Academic Press Inc., San Diego. 
Pyke, C., Kristensen, P., Ralfkiier, E.. Grendahl-Hansen, J., 
Eriksen, J.. Blasi, F. and Dana, K. (1991) Am. J. Pathol. 138, 
1059-1067. 
Kyte, J. and Doolittle, R.F. (1992) J. Mol. Biol. 157, 1055132. 
Ranne, E., Behrendt, N., Ellis, V., Ploug, M., Dana, K. and 
Hoyer-Hansen, G. (1991) FEBS Lett. 288, 233-236. 
[21] Ellis, V. and Dana, K. (1993) J. Biol. Chem. (in press) 
74 
